Skip to main content
. 2022 Jun 15;13(5):13893–13905. doi: 10.1080/21655979.2022.2086377

Figure 3.

Figure 3.

Knockdown of HOXA11-AS expression could enhance cisplatin sensitivity of ovarian cancer cells. (a) GSE15372 dataset exhibits that HOXA11-AS expression was higher in cisplatin-resistant A2780/DDP cells than cisplatin-sensitive A2780 cells. (b, c) qRT-PCR assays showed HOXA11-AS expression and transfection efficiency in A2780/DDP cells. (d) CCK-8 method showed the effect of low expression of HOXA11-AS on cisplatin sensitivity of A2780/DDP cells. ** P < 0.01, *** P < 0.001 and **** P < 0.0001 vs. respective con-HOXA11-AS, n = 3, Mean ± SD.